Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) declared a quarterly cash dividend of $0.63 per share. The Board set the dividend payable on May 1, 2026 to shareholders of record as of April 2, 2026.
This action returns cash to shareholders and reflects a scheduled quarterly distribution policy.
SystImmune and Bristol Myers Squibb (NYSE: BMY) reported that izalontamab brengitecan (iza-bren) met both dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in a pre-specified interim analysis of a Phase III study (BL-B01D1-307; NCT06382142) in previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in China.
This is the third Phase III trial where iza-bren reached primary endpoint(s) and the first bispecific ADC in Phase III to report dual positive PFS/OS results in TNBC; data will be presented at an upcoming medical meeting.
Bristol Myers Squibb (NYSE: BMY) will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company will appear in a fireside chat beginning at 9:50 a.m. ET.
Investors and the public can listen via the company investor site at http://investor.bms.com, and an archived recording will be available after the session.
Bristol Myers Squibb (NYSE: BMY) reported positive top-line results from an ex‑US Phase 2 registrational study (NCT05664737) of Reblozyl (luspatercept) in adults with alpha (α)-thalassemia.
Both non‑transfusion‑dependent and transfusion‑dependent cohorts met primary and key secondary endpoints: an Hb increase in NTD and ≥50% RBC transfusion reduction in TD. Safety matched Reblozyl's known profile. Data will be presented at a medical congress and discussed with China's regulator.
Bristol Myers Squibb (NYSE: BMY) announced the FDA has accepted the New Drug Application for iberdomide in relapsed or refractory multiple myeloma with a PDUFA target action date of August 17, 2026. The submission is based on MRD negativity results from the Phase 3 EXCALIBER-RRMM study (Stage 2 ~664 patients) and received Breakthrough Therapy designation.
The review is part of FDA Project Orbis for concurrent international review; EXCALIBER remains ongoing and PFS data are still maturing.
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter and full-year 2025 financial results and will host a conference call and live audio webcast at 8:00 a.m. ET on February 5, 2026. A replay will be available on the company’s investor site about three hours after the call.
Investor and media contact emails are provided for follow-up.
Bristol Myers Squibb (NYSE: BMY) announced a partnership with soccer Hall-of-Famer Kasey Keller, who for the first time is publicly sharing his non-Hodgkin lymphoma journey and one-time treatment with Breyanzi (lisocabtagene maraleucel) to raise awareness on World Cancer Day.
The release highlights Breyanzi’s five FDA-approved indications, a 3-year follow-up showing a 62% average reduction in risk versus standard care, and Important Safety Information including Boxed WARNINGS for CRS, neurologic toxicities, and secondary hematologic malignancies.
Bristol Myers Squibb (NYSE: BMY) launched an educational campaign, "Change the Target. Change What’s Possible.", developed with Johnson & Johnson to highlight unmet needs in cardiovascular and thromboembolic care and the emerging research interest in factor XIa (FXIa) as a potential target.
The program cites that 40% of atrial fibrillation patients are untreated or undertreated and that roughly 25% of strokes are recurrent, noting bleeding risk as a key gap in current therapies. Resources are available at www.factorxi.com.
Bristol Myers Squibb (NYSE: BMS) announced a collaboration with Microsoft on January 20, 2026 to deploy U.S. FDA-cleared radiology AI algorithms for lung cancer detection via Microsoft’s Precision Imaging Network. The initiative aims to automatically analyze X-ray and CT images to surface hard-to-detect lung nodules, accelerate identification of potential Non‑Small Cell Lung Cancer (NSCLC) cases, and route patients into care pathways.
The program emphasizes expanding early detection and follow-up in medically underserved communities, leveraging workflow tools to address that >50% of patients with incidental findings are lost to follow-up and noting Microsoft’s network reaches more than 80% of U.S. hospitals.
Bristol Myers Squibb (NYSE: BMY) announced positive topline Phase 3 SCOUT-HCM results showing Camzyos (mavacamten) met the primary endpoint with a statistically significant reduction in Valsalva LVOT gradient at Week 28 versus placebo in adolescents (ages 12 to <18).
The 44‑patient trial also met multiple secondary endpoints, reported safety consistent with the adult profile with no new signals, and continues into active treatment and a long‑term extension (totaling up to 200 weeks).